{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:32:53Z","timestamp":1793219573318,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-21-RHUS-0014"],"award-info":[{"award-number":["ANR-21-RHUS-0014"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurol.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:34:40Z","timestamp":1784633680000},"page":"736-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multi-outcome prognostic score for therapeutic responses in multiple sclerosis"],"prefix":"10.1016","volume":"182","author":[{"given":"J.","family":"Louet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6148-4676","authenticated-orcid":false,"given":"J.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5735-0173","authenticated-orcid":false,"given":"I.","family":"Faddeenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8375-7530","authenticated-orcid":false,"given":"M.","family":"Payet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Baciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5918-9261","authenticated-orcid":false,"given":"R.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"De S\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-A.","family":"Laplaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Edan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-9554","authenticated-orcid":false,"given":"P.-A.","family":"Gourraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2504-5294","authenticated-orcid":false,"given":"S.","family":"Demuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neurol.2026.06.003_bib0185","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40263-015-0251-1","article-title":"Platform therapy compared with natalizumab for multiple sclerosis: relapse rates and time to relapse among Propensity Score-Matched US Patients","volume":"29","author":"Johnson","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurol.2026.06.003_bib0190","doi-asserted-by":"crossref","first-page":"102686","DOI":"10.1016\/j.msard.2020.102686","article-title":"First line treatment failure: predictive factors in a cohort of 863 relapsing remitting MS patients","volume":"48","author":"Ayrignac","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.neurol.2026.06.003_bib0195","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12026-018-9032-5","article-title":"Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale","volume":"66","author":"Karussis","year":"2018","journal-title":"Immunol Res"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.003_bib0200","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","article-title":"High-efficacy therapy discontinuation vs. continuation in patients 50 years and older with nonactive MS","volume":"81","author":"Jouvenot","year":"2024","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.003_bib0205","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs. relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"issue":"4\u20135","key":"10.1016\/j.neurol.2026.06.003_bib0210","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/13524585231157211","article-title":"The impact of relapse definition and measures of durability on MS clinical trial outcomes","volume":"29","author":"Satyanarayan","year":"2023","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.neurol.2026.06.003_bib0215","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jamaneurol.2024.1961","article-title":"Acute clinical events identified as relapses with stable magnetic resonance imaging in multiple sclerosis","volume":"81","author":"Gavoille","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.06.003_bib0220","doi-asserted-by":"crossref","first-page":"101928","DOI":"10.1016\/j.msard.2020.101928","article-title":"Predictive medicine in multiple sclerosis: a systematic review","volume":"40","author":"Havas","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.neurol.2026.06.003_bib0225","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1212\/WNL.0000000000002830","article-title":"Assessing response to interferon-\u03b2 in a multicenter dataset of patients with MS","volume":"87","author":"Sormani","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.003_bib0230","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neurad.2020.01.083","article-title":"New OFSEP recommendations for MRI assessment of multiple sclerosis patients: special consideration for gadolinium deposition and frequent acquisitions","volume":"47","author":"Brisset","year":"2020","journal-title":"J Neuroradiol"},{"key":"10.1016\/j.neurol.2026.06.003_bib0235","doi-asserted-by":"crossref","first-page":"856829","DOI":"10.3389\/fdgth.2022.856829","article-title":"PHREND\u00ae \u2013 A real-world data-driven tool supporting clinical decisions to optimize treatment in relapsing-remitting multiple sclerosis","volume":"4","author":"Braune","year":"2022","journal-title":"Front Digit Health"},{"key":"10.1016\/j.neurol.2026.06.003_bib0240","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41746-020-00338-8","article-title":"Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study","volume":"3","author":"Zhao","year":"2020","journal-title":"NPJ Digit Med"},{"issue":"8","key":"10.1016\/j.neurol.2026.06.003_bib0245","doi-asserted-by":"crossref","first-page":"100119","DOI":"10.1016\/j.patter.2020.100119","article-title":"Inference and prediction diverge in biomedicine","volume":"1","author":"Bzdok","year":"2020","journal-title":"Patterns N Y N"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.003_bib0250","doi-asserted-by":"crossref","first-page":"ooag039","DOI":"10.1093\/jamiaopen\/ooag039","article-title":"PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis","volume":"9","author":"Demuth","year":"2026","journal-title":"JAMIA Open"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.003_bib0255","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","article-title":"Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial","volume":"11","author":"Comi","year":"2012","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.003_bib0260","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.003_bib0265","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.neurol.2026.06.003_bib0270","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.neurol.2026.06.003_bib0275","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.003_bib0280","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2026.06.003_bib0285","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1177\/1352458514557986","article-title":"Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE","volume":"21","author":"Kieseier","year":"2015","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.003_bib0290","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.003_bib0295","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.003_bib0300","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1352458518815602","article-title":"Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques (OFSEP): a unique multimodal nationwide MS registry in France","volume":"26","author":"Vukusic","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.06.003_bib0305","unstructured":"OFSEP\u00a0\u2013\u00a0Home. Accessed June 26, 2024. https:\/\/www.ofsep.org\/en\/."},{"issue":"3","key":"10.1016\/j.neurol.2026.06.003_bib0310","doi-asserted-by":"crossref","first-page":"ooag039","DOI":"10.1093\/jamiaopen\/ooag039","article-title":"PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis","volume":"9","author":"Demuth","year":"2026","journal-title":"JAMIA Open"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.003_bib0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of \u201cno evidence of disease activity\u201d in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.003_bib0320","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/2193-1801-2-222","article-title":"Principled missing data methods for researchers","volume":"2","author":"Dong","year":"2013","journal-title":"SpringerPlus"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.003_bib0325","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1007\/s10994-023-06336-7","article-title":"Classifier Calibration: a survey on how to assess and improve predicted class probabilities","volume":"112","author":"Filho","year":"2023","journal-title":"Mach Learn"},{"key":"10.1016\/j.neurol.2026.06.003_bib0330","unstructured":"PRIMUS research use only prototypes. https:\/\/primusruotest.chu-nantes.fr\/."},{"issue":"1","key":"10.1016\/j.neurol.2026.06.003_bib0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gheart.2013.01.001","article-title":"Cardiovascular disease risk assessment: insights from Framingham","volume":"8","author":"D\u2019Agostino","year":"2013","journal-title":"Glob Heart"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.003_bib0340","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/cpt.1210","article-title":"Using real-world data to extrapolate evidence from randomized controlled trials","volume":"105","author":"Wang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.003_bib0345","first-page":"CD013606","article-title":"Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis","volume":"9","author":"Reeve","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.neurol.2026.06.003_bib0350","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41551-021-00751-8","article-title":"Synthetic data in machine learning for medicine and healthcare","volume":"5","author":"Chen","year":"2021","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.003_bib0355","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1038\/s41598-024-58141-4","article-title":"Data-driven normative values based on generative manifold learning for quantitative MRI","volume":"14","author":"Atty\u00e9","year":"2024","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.neurol.2026.06.003_bib0360","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/acn3.51649","article-title":"Multiple sclerosis clinical decision support system based on projection to reference datasets","volume":"9","author":"Ed-Driouch","year":"2022","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:50:18Z","timestamp":1793217018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726005606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0035378726005606"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.06.003","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multi-outcome prognostic score for therapeutic responses in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}